Private Equity 8 Hours

Last updated: April 29, 2026, 2:30 AM ET

European Tech & Venture Capital Shifts

Venture capital firms are recalibrating strategies amid geopolitical volatility, with Kompas VC focusing on startups addressing tangible, physical-world needs as global fragmentation complicates traditional cross-border investing models. This shift comes as European regulators eye potential market control issues, with UK authorities examining dangers posed by technology chokepoints, reflecting growing sovereign concerns over digital dependency. On the deal-sourcing front, venture capitalists are actively tracking emerging ecosystems, identifying sixteen French startups warranting close attention, while simultaneously noting the maturation of secondary markets like those in Europe’s fastest-rising ‘tier two’ hubs as primary funding rounds become more selective, 3.

Biotech Litigation & IP Risks

The intellectual property environment continues to present hazards for growth-stage technology investments, exemplified by the IP lawsuit facing the GV-backed biotech startup OMass. Such litigation underscores the heightened due diligence required in sectors where proprietary technology is the core asset, especially as private equity looks to deploy capital into specialized life sciences firms.